MDACC Study No:2010-0266 ( NCT No: NCT01258933)
Title:Ofatumumab for Residual Disease and Maintenance Following Chemotherapy or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Principal Investigator:William G. Wierda
Treatment Agent:Ofatumumab
Study Status:Closed
Study Description:The goal of this clinical research study is to find out if ofatumumab can
control CLL or SLL that is left after chemotherapy or chemoimmunotherapy. The
safety of the drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Ofatumumab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:GlaxoSmithKline
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-745-0428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults